Clinical trial NCT00823316: Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation
Official title: Phase 1/2 Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells Infusion for Promotion of Engraftment and Prevention of an Graft Rejection and Graft-versus-Host Disease After Unrelated Hematopoietic Stem Cell Transplantation.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Acute Leukemia
Keywords: Mesenchymal Stem Cells
Allogeneic Transplantation
Engraftment
GvHD
Childhood
unrelated HSCT
Lead sponsor: Medipost Co Ltd.
Sponsor class: INDUSTRY
First posted: 2009-01-15
Enrollment: 10
Sex: ALL
Minimum age (years): 2
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of PROMOSTEM (human umbilical cord blood-derived mesenchymal stem cells) at a dose of 1 and 5x1,000,000 hMSC/kg in subject for the promotion of an engraftment and prevention of graft rejection and Graft-Versus-Host Disease after unrelated hematopoietic stem cell transplantation for children with acute leukemia.

Detailed description: * Hematopoietic stem cell transplantation (HSCT) is a procedure in which progenitor cells capable of reconstituting normal bone marrow function are administered to a patient. This procedure has been used to treat adults and children with life-threatening hematological malignancies and congenital immunodeficiency disorders.
* In HSCT, therapeutic goal is an elimination of disease and enrichment of regenerating capacity to achieve engraftments resulting in continued generation of functional blood elements from the engrafted living cells. Transplantation of unrelated hematopoietic stem cells originating either from adult bone marrow or from peripheral blood often leads to graft-versus host-disease (GvHD), opportunistic infections and graft failure after transplantation.
* In HSCT, MSC have been used as a therapy for GvHD and other complications. The aim of MSC infusions in HSCT is to use the cells' immunomodulatory effects to promote engraftment and to reduce the immunological reactions giving rise to GvHD.
* There is a growing interest in co-transplantation of MSC and HSC to improve the donor outcome in the unrelated HSCT condition.

Eligibility criteria: Inclusion Criteria:

1. Patient age 2\~19 years old with plan to have unrelated hematopoietic stem cell transplantation with acute leukemia
2. Patient never has an experience of hematopoietic stem cell transplantation
3. Patient must have an acute leukemia with a complete remission.
4. Patients must have an ECOG 0\~2.
5. No moderate or sever organ dysfunction : Ejection fraction \> 45%; Creatinine \<2.0 mg/ml; Serum bilirubin \< 2 mg/ml; AST/ALT \< 200 IU/L.
6. Patient must not have an transplantation with different source of hematopoietic stem cell such as bone marrow and cord blood.
7. Patient must not have an infection needed an administration of non-oral antibiotics.
8. No active severe infection derived form virus or fungus.
9. Each patient / patient's guardian must sign written informed consent.

Exclusion Criteria:

1. Patient has previously received hematopoietic stem cell transplantation.
2. Patient plans to have a related hematopoietic stem cell transplantation.
3. Patient has a severe internal disease.
4. Patient has enrolled another clinical trial study within last 4 weeks.

Primary outcomes:
measure: - Day of neutrophil engraftment - Day of platelet engraftment - Evaluation of chimerism - Evaluation of engraftment rate
timeFrame: 28 and 100 days
Secondary outcomes:
measure: - AGVHD grade
timeFrame: 100 days
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Hong Hoe Koo, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: